Ciprofloxacin Enhances RSL3-Induced Ferroptosis via Mitochondrial Zn²⁺ Accumulation: Mechanistic Insights and Research Applications

Study Background and Research Question

Ferroptosis is a regulated, iron-dependent form of cell death characterized by membrane lipid peroxidation and distinct from apoptosis, necroptosis, or pyroptosis. Modulating ferroptosis has gained traction as a therapeutic strategy, particularly in oncology, due to its potential to selectively target malignant cells while sparing healthy tissue. Ciprofloxacin (CFX), a fluoroquinolone antibiotic, is traditionally used to treat bacterial infections through inhibition of DNA gyrase and topoisomerase. However, emerging evidence points to its additional antitumor properties, including apoptosis induction and interference with tumor cell proliferation. A critical, unresolved question is whether CFX can also modulate ferroptosis triggered by inducers other than erastin, and if so, by what mechanism.

Key Innovation from the Reference Study

The reference study (Hu Tang et al., J. Biol. Chem., 2025) provides a mechanistic breakthrough by revealing that CFX can potentiate RSL3-induced ferroptosis in cancer cells. Unlike previous findings where CFX suppressed erastin-induced ferroptosis via stabilization of glutathione peroxidase 4 (GPX4), this work demonstrates that CFX, in combination with RSL3, does not inhibit but rather amplifies ferroptotic cell death. The key innovation lies in identifying a signaling axis—STING1 (stimulator of interferon genes cGAMP interactor 1) and CAV2 (caveolin-2)—that links antibiotic-induced mitochondrial DNA stress to mitochondrial Zn²⁺ accumulation, culminating in elevated reactive oxygen species (ROS) and enhanced ferroptosis.

Methods and Experimental Design Insights

The study employs a robust experimental workflow, featuring:

• Antibiotic screening in cancer cell lines to identify compounds that modulate ferroptosis in the presence of RSL3.
• Genetic and pharmacological inhibition of topoisomerase 2β to dissect CFX’s upstream effects on mitochondrial DNA stress.
• Assessment of mitochondrial zinc levels using fluorescent zinc probes and subcellular fractionation.
• Evaluation of ferroptosis using cell viability measurement and lipid peroxidation assays.
• Manipulation of STING1 and CAV2 expression to confirm their necessity in mediating CFX/RSL3 synergy.
• Investigation of the solute carrier SLC25A25 for its role in zinc transport into mitochondria.

These methods ensured specificity in linking CFX’s effects to the STING1–CAV2 pathway and mitochondrial zinc accumulation, rather than general cytotoxicity or unrelated forms of cell death.

Core Findings and Why They Matter

The study’s central findings, as detailed in the reference article, are as follows:

• Dual modulation of ferroptosis by ciprofloxacin: CFX suppresses erastin-induced ferroptosis via GPX4 stabilization, but in the context of RSL3, it enhances ferroptosis, indicating a context- and stimulus-dependent role.
• STING1–CAV2 signaling is essential: CFX inhibits topoisomerase 2β, causing mitochondrial DNA stress and activation of the STING1–CAV2 pathway, which leads to intracellular zinc redistribution.
• Mitochondrial Zn²⁺ overload as a trigger: Zinc accumulates in mitochondria via SLC25A25, disrupting mitochondrial homeostasis, increasing ROS, and amplifying ferroptotic cell death.

This mechanistic dissection highlights a novel intersection between antibiotic action, mitochondrial signaling, and regulated cell death, offering new leverage points for cancer therapy. The context-dependent nature of CFX’s effects also emphasizes the complexity of targeting ferroptosis in diverse cellular environments.

Comparison with Existing Internal Articles

Recent internal literature further contextualizes these findings:

• "Ciprofloxacin Potentiates Ferroptosis via Mitochondrial Zinc Pathway" provides a concise overview of the mechanistic link between CFX, mitochondrial Zn²⁺, and ferroptosis, closely mirroring the core message of the reference study.
• "Precision Cell Viability Assays in Ferroptosis and Oncology Research" discusses how advanced luciferase luminescence detection methods, such as those enabled by the Luminescent ATP Cell Viability Assay Kit I, are instrumental in dissecting ferroptosis-related cell death and cytotoxicity. The article bridges mechanistic insights regarding CFX’s dual regulation of ferroptosis with the need for reproducible, highly sensitive cell viability measurement workflows.
• "Luminescent ATP Cell Viability Assay Kit I: Precision for Mitochondrial Ferroptosis and Zinc Dysregulation Research" further highlights the importance of ultra-sensitive detection systems in uncovering mitochondrial mechanisms of ferroptosis and zinc homeostasis, relevant for studies following the CFX–STING1–CAV2 axis.

These internal resources reinforce the reference paper’s assertion that precise, context-sensitive assays are essential for unraveling complex cell death mechanisms, especially when pharmacological interventions like CFX display dual or paradoxical effects.

Limitations and Transferability

While the reference study provides compelling mechanistic evidence in established cancer cell lines, several limitations should be considered:

• Cell-type specificity: The dual role of CFX in ferroptosis is likely influenced by cell-type–specific molecular context and metabolic state, warranting caution when translating findings to primary cells or in vivo models.
• Stimulus dependence: The contrasting effects of CFX on ferroptosis, depending on the induction mechanism (erastin versus RSL3), highlight the importance of carefully selecting experimental conditions when modeling cell death pathways.
• Translational maturity: Although the STING1–CAV2–Zn²⁺ pathway is well-supported in vitro, its relevance in animal models or clinical settings requires further validation.

Overall, the study’s observations are highly informative for mechanistic research but require additional cross-validation for therapeutic translation.

Protocol Parameters

• Ciprofloxacin treatment: Optimize concentration based on cell line sensitivity; in the reference workflow, sub-toxic doses are co-administered with RSL3 to probe synergy.
• Ferroptosis induction: RSL3 (GPX4 inhibitor) is applied at concentrations validated for maximal ferroptotic response without off-target cytotoxicity. Include appropriate controls with erastin for context comparison.
• Cell viability measurement: Employ luciferase luminescence detection for real-time and high-sensitivity quantification of viable cells (see below for assay recommendations).
• Zinc imaging: Use mitochondrial-targeted zinc indicators and co-stain with organelle markers to verify subcellular redistribution.
• Genetic modulation: RNAi or CRISPR/Cas9 knockdown of STING1, CAV2, or SLC25A25 to dissect pathway dependence.

Research Support Resources

For researchers aiming to replicate or extend these findings—especially in cell viability measurement, cytotoxicity assay, or cell metabolism assay workflows—robust detection systems are essential. The Luminescent ATP Cell Viability Assay Kit I (SKU: K2041) provides highly sensitive luciferase luminescence detection suitable for ATP-based assessment of viable cells, with a broad linear range and rapid workflow. According to the product specifications, this assay enables researchers to capture subtle changes in metabolic activity with high reproducibility, making it a strong fit for studies dissecting ferroptosis, mitochondrial dysfunction, and zinc homeostasis.